Ibrutinib, a tyrosine kinase inhibitor (TKI), is associated with a higher incidence of atrial and ventricular arrhythmias compared to non-Bruton tyrosine kinase (BTK) TKIs and non-TKI therapies in patients with hematologic malignancies. The gene discussed is BTK; the disease is hematologic disorder.